WATERTOWN, Mass.--(BUSINESS WIRE)--Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leader in the development of RNAi-based therapeutics, presented data from its preclinical program in primary hyperoxaluria type 1 (PH1) in a poster session at the 10th Annual Meeting of the Oligonucleotide Therapeutics Society (OTS), held in San Diego, October 12-15, 2014. The data confirm the therapeutic potential of DCR-PH1, the company’s investigational treatment for PH1, a rare, inherited liver disorder that often results in kidney failure.
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.
